An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia.
A
A
Agarwal
C A
CA
Eide
A
A
Harlow
A S
AS
Corbin
M J
MJ
Mauro
B J
BJ
Druker
C L
CL
Corless
M C
MC
Heinrich
M W
MW
Deininger
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D016283:Proto-Oncogene Proteins p21(ras); D011743:Pyrimidines / Q000627:therapeutic use*; D018631:ras Proteins / Q000235:genetics*
D000970:Antineoplastic Agents; D001549:Benzamides; C117307:KRAS protein, human; D010879:Piperazines; D011518:Proto-Oncogene Proteins; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins